

Revance Therapeutics Investor Relations Department 7555 Gateway Boulevard Newark, CA 94560 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: RVNC	
Last Trade:	25.50
Trade Time:	4:00 PM ET Oct 20, 2017
Change:	-0.35 🖶 (-1.354%)
Day Range	25.05 - 26.00
52-Week Range	12.35 - 28.75
Volume	119,551


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance's science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance's initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthe... (more)

Stock Performance



Press Releases [View all]

Oct 18, 2017

Revance Therapeutics to Release Third
Quarter 2017 Financial Results Thursday,
November 2, 2017

Oct 18, 2017

Revance Completes Patient Enrollment in
Phase 2 Program for RT002 Injectable in the
Management of Plantar Fasciitis

Sep 19, 2017

Revance to Participate in the Cantor Fitzgerald 2017 Global Healthcare Conference

Sep 6, 2017

Revance Appoints Mark Foley to its Board of <u>Directors</u>

Aug 30, 2017

Revance to Participate in the 2017 Wells Fargo Securities Healthcare Conference

Upcoming Events [View all]

Nov 2, 2017 4:30 PM ET
Revance Therapeutics 2017 Third Quarter
Financial Results

Financials [View all]

Second Quarter Financial Results

Feb 28, 2017 Annual Report (10-K)

Mar 24, 2017 Proxy Statement (DEF 14A)

Aug 4, 2017

Quarterly Report (10-Q)

May 9, 2017 Quarterly Report (10-Q)

Nov 4, 2016

Quarterly Report (10-Q)